Kemp JV - Search Results

1

Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition.

McKillop D, Guy SP, Spence MP, Kendrew J, Kemp JV, Bushby N, Wood PG, Barnett S, Hutchison M. McKillop D, et al. Among authors: kemp jv. Xenobiotica. 2006 Jan;36(1):29-39. doi: 10.1080/00498250500523253. Xenobiotica. 2006. PMID: 16507511

2

Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor.

McKillop D, Partridge EA, Kemp JV, Spence MP, Kendrew J, Barnett S, Wood PG, Giles PB, Patterson AB, Bichat F, Guilbaud N, Stephens TC. McKillop D, et al. Among authors: kemp jv. Mol Cancer Ther. 2005 Apr;4(4):641-9. doi: 10.1158/1535-7163.MCT-04-0329. Mol Cancer Ther. 2005. PMID: 15827338

3

Disposition and metabolism of the specific endothelin A receptor antagonist zibotentan (ZD4054) in healthy volunteers.

Clarkson-Jones JA, Kenyon AS, Kemp J, Lenz EM, Oliver SD, Swaisland H. Clarkson-Jones JA, et al. Xenobiotica. 2012 Apr;42(4):363-71. doi: 10.3109/00498254.2011.624204. Epub 2011 Oct 20. Xenobiotica. 2012. PMID: 22014279

4

Population pharmacokinetic/pharmacodynamic modelling of the anti-TNF-α polyclonal fragment antibody AZD9773 in patients with severe sepsis.

Yates JW, Das S, Mainwaring G, Kemp J. Yates JW, et al. J Pharmacokinet Pharmacodyn. 2012 Dec;39(6):591-9. doi: 10.1007/s10928-012-9270-4. Epub 2012 Sep 23. J Pharmacokinet Pharmacodyn. 2012. PMID: 23001587 Clinical Trial.

5

Pharmacokinetics, dose proportionality, and tolerability of single and repeat doses of a nasal spray formulation of zolmitriptan in healthy volunteers.

Yates R, Nairn K, Dixon R, Kemp JV, Dane AL. Yates R, et al. Among authors: kemp jv. J Clin Pharmacol. 2002 Nov;42(11):1244-50. doi: 10.1177/009127002762491334. J Clin Pharmacol. 2002. PMID: 12412823 Clinical Trial.

6

The pharmacokinetics of the antimigraine compound zolmitriptan in Japanese and Caucasian subjects.

Yates RA, Tateno M, Nairn K, Ikegami A, Dane A, Kemp J. Yates RA, et al. Eur J Clin Pharmacol. 2002 Jul;58(4):247-52. doi: 10.1007/s00228-002-0461-6. Epub 2002 May 25. Eur J Clin Pharmacol. 2002. PMID: 12136370 Clinical Trial.

7

Distribution of intranasal C-zolmitriptan assessed by positron emission tomography.

Yates R, Sörensen J, Bergström M, Antoni G, Nairn K, Kemp J, Långström B, Dane A. Yates R, et al. Cephalalgia. 2005 Dec;25(12):1103-9. doi: 10.1111/j.1468-2982.2005.00966.x. Cephalalgia. 2005. PMID: 16305598 Clinical Trial.

8

Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies.

Tomkinson H, Kemp J, Oliver S, Swaisland H, Taboada M, Morris T. Tomkinson H, et al. BMC Clin Pharmacol. 2011 Mar 17;11:3. doi: 10.1186/1472-6904-11-3. BMC Clin Pharmacol. 2011. PMID: 21414193 Free PMC article. Clinical Trial.

9

An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.

Tomkinson HK, Kemp JV, Wollseifen T, Morris T, Oliver SD. Tomkinson HK, et al. Among authors: kemp jv. Clin Ther. 2010 Jul;32(7):1372-86. doi: 10.1016/j.clinthera.2010.07.013. Clin Ther. 2010. PMID: 20678684 Clinical Trial.

10

The metabolism of zolmitriptan: effects of an inducer and an inhibitor of cytochrome p450 on its pharmacokinetics in healthy volunteers.

Dixon R, French S, Kemp J, Sellers M, Yates R. Dixon R, et al. Clin Drug Investig. 1998;15(6):515-22. doi: 10.2165/00044011-199815060-00008. Clin Drug Investig. 1998. PMID: 18370509

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28 results

Search Page

Filters